CTNM — Contineum Therapeutics Share Price
0.000.00%
Last trade - 00:00- $106.07m
- -$98.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.54 | ||
| Price to Tang. Book | 0.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.09% | ||
| Return on Equity | -26.19% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 50 | n/a | 5 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 7th, 2009
- Public Since
- April 5th, 2024
- No. of Shareholders
- 39
- No. of Employees
- 41
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 25,871,549
- Address
- 3565 General Atomics Court, Suite 200, SAN DIEGO, 92121
- Web
- https://www.contineum-tx.com/
- Phone
- +1 8583335280
- Auditors
- Ernst & Young LLP
Upcoming Events for CTNM
Similar to CTNM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Contineum Therapeutics share price?
As of Today at 20:04 UTC, shares in Contineum Therapeutics are trading at $4.10. This share price information is delayed by 15 minutes.
How has the Contineum Therapeutics share price performed this year?
Shares in Contineum Therapeutics last closed at $4.10 and the price had moved by -72.48% over the past 365 days. In terms of relative price strength the Contineum Therapeutics share price has underperformed the S&P500 Index by -75.19% over the past year.
What are the analyst and broker recommendations for Contineum Therapeutics?
The overall consensus recommendation for Contineum Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Contineum Therapeutics dividend yield?
Contineum Therapeutics does not currently pay a dividend.
Does Contineum Therapeutics pay a dividend?
Contineum Therapeutics does not currently pay a dividend.
When does Contineum Therapeutics next pay dividends?
Contineum Therapeutics does not currently pay a dividend.
How do I buy Contineum Therapeutics shares?
To buy shares in Contineum Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Contineum Therapeutics?
As of the previous close price of $4.10, shares in Contineum Therapeutics had a market capitalisation of $106.07m.
Where are Contineum Therapeutics shares listed?
Here are the trading details for Contineum Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CTNM
What kind of share is Contineum Therapeutics?
Based on an overall assessment of its quality, value and momentum Contineum Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Contineum Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Contineum Therapeutics is $24.80. That is 504.88% above the last closing price of $4.10.
Analysts covering Contineum Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.26 for the next financial year.
Find out moreWhat is the trend in the Contineum Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Contineum Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -75.26%.
As of the last closing price of $4.10, shares in Contineum Therapeutics were trading -69.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Contineum Therapeutics PE Ratio?
The Contineum Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Contineum Therapeutics?
We do not have data on Contineum Therapeutics' directors